Table 1.
Drug Preparations
| Drug | Drug Action | Volume Given Daily (µL) | Amount Administered (µmol/d) | Concentration: Drug Solution (mM) | Estimated Vitreal Concentration (µM) |
|---|---|---|---|---|---|
| Dopamine | Natural ligand | 10 | 1.500 | 150.00 | 7500 |
| 0.150 | 15.00 | 750 | |||
| 0.015 | 1.50 | 75 | |||
| 0.002 | 0.15 | 10 | |||
| ADTN | Nonspecific agonist | 10 | 1.000 | 100.00 | 5000 |
| 0.100 | 10.00 | 500 | |||
| 0.010 | 1.00 | 50 | |||
| 0.001 | 0.10 | 5 | |||
| Dopamine/SCH-23390 | Natural ligand/D1-like antagonist | 10 | 0.150/0.005 | 15.00/0.50 | 750/25 |
| Dopamine/spiperone | Natural ligand/D2-like antagonist | 10 | 0.150/0.005 | 15.00/0.50 | 750/25 |
| ADTN/SCH-23390 | Nonspecific agonist/D1-like antagonist | 10 | 0.100/0.005 | 10.00/0.50 | 500/25 |
| ADTN/spiperone | Nonspecific agonist/D2-like antagonist | 10 | 0.100/0.005 | 10.00/0.50 | 500/25 |
Each drug preparation was administered to both FDM- and LIM-treated eyes; 0.150 µmol dopamine and 0.100 µmol ADTN were also administered to eyes receiving no other ocular treatment to examine their effects on normal ocular development. Vitreal concentration was estimated from an average vitreous volume of 200 µL at this age. Molar mass (g/mol)—dopamine (189.64), ADTN (260.13), SCH-23390 (324.24), and spiperone (395.47).